Adlai Nortye Group Ltd. (ANL)

Price$15.01Cached quoteAs of 2026-09-05 01:16 UTC

AI: Overvalued

Price checkThe balance sheet is strong, but the market is assigning substantial value to oncology programs that are still largely in early clinical development.

With about 64.4 million ADS-equivalent shares outstanding, the equity value is roughly $1.0 billion. June liquidity included $132.6 million of cash plus $99.3 million of short-term investments, while total debt was about $26.7 million, implying roughly $205 million of net cash and an enterprise value near $0.8 billion. That is a demanding valuation for a company whose two principal RAS programs are in Phase I and whose most advanced prior asset, buparlisib, failed the primary overall-survival endpoint in the Phase III BURAN trial. The valuation can be justified only if the newer RAS pipeline produces clinically differentiated human data.

Big pictureThe investment thesis has shifted decisively toward next-generation RAS-targeted oncology, led by AN9025 and AN4035, with the first meaningful human efficacy readouts expected in 2027.

AN9025 is an oral pan-RAS(ON) inhibitor being tested in both daily and intermittent weekly Phase I dosing arms in patients with RAS-mutated solid tumors, with initial Phase Ia data targeted for the first half of 2027. AN4035 combines a CEACAM5-targeting antibody-drug conjugate with a pan-RAS(ON) inhibitor payload; its first patient was dosed in September and the FDA cleared its U.S. IND, with initial clinical data expected in the second half of 2027. AN8025 remains in Phase I and AN0025 has completed enrollment in a randomized Phase II rectal-cancer study with topline results expected in the first half of 2027. Recent revenue is licensing-related rather than product sales.

Business strengthLarge 2026 equity financings provide a substantial cash runway and the ASK Pharm licensing deal offers external validation, but dilution has already been significant and could continue.

Cash and short-term investments totaled $231.9 million at June while first-half operating cash use was $15.4 million, giving the company considerable near-term flexibility even as clinical spending rises. Adlai Nortye raised $140 million in a February private placement and another $150 million in April. Its AN9025 agreement with ASK Pharm gives ASK rights in mainland China, Hong Kong and Macao while Adlai Nortye retains ex-China rights; potential consideration totals up to about $230 million, including more than $20 million of upfront and near-term milestones plus royalties. However, outstanding ordinary shares increased sharply during the first half, and shareholders are being asked to authorize issuance of up to another 90 million Class A shares, leaving a meaningful dilution overhang.

What could change the storyPositive human RAS data could rapidly de-risk the pipeline, while weak efficacy, toxicity, competitive pressure or further dilution would challenge the current valuation.

The strongest bull catalyst would be clear tumor responses and an acceptable therapeutic window from AN9025 in early 2027, followed by encouraging AN4035 data and additional ASK milestone payments or partnerships. AN0025 Phase II results and progression of AN8025 provide secondary optionality. The bear case is substantial: RAS drug development is increasingly competitive, and Revolution Medicines' broad RAS inhibitor daraxonrasib received FDA approval for metastatic pancreatic cancer in August 2026, meaning Adlai Nortye will ultimately need to demonstrate meaningful differentiation. Its own claims of superior AN9025 potency versus competing RAS inhibitors are currently based largely on preclinical comparisons. The failed Phase III BURAN study illustrates clinical-development risk, while the large shelf registration and proposed additional share authority preserve significant future financing capacity that could dilute existing holders.

AI: News

AN4035 entered the clinic with U.S. FDA clearanceThe company's RAS-inhibitor ADC reached its first human dosing milestone and gained clearance to expand the Phase I study into the United States.

Adlai Nortye dosed the first AN4035 patient in Australia in September and received an FDA Study-May-Proceed letter for its U.S. IND. The global Phase I study targets CEACAM5-enriched, RAS-addicted solid tumors and is intended to test whether tumor-selective delivery of a pan-RAS(ON) inhibitor can improve the therapeutic window relative to systemic RAS inhibition. Initial clinical data are planned for the second half of 2027.

First-half results highlighted a much stronger funding positionTwo private placements transformed the balance sheet while the ASK Pharm agreement generated the company's first meaningful recent licensing revenue.

June cash and short-term investments reached $231.9 million after equity financings totaling $290 million before fees during the first half. Six-month revenue was $13.1 million, entirely from the AN9025 licensing agreement with ASK Pharm, while the net loss narrowed to $5.3 million and operating cash use was $15.4 million. The improved liquidity materially extends development runway but came with substantial share issuance.

AN9025 expanded into intermittent weekly dosingBoth daily and weekly Phase I dosing strategies are now enrolling, giving the company two approaches for optimizing efficacy and tolerability.

The first U.S. patient in the once-weekly AN9025 arm was dosed in July, joining the once-daily arm that began dosing earlier in 2026. Management believes intermittent exposure could widen the therapeutic window based on preclinical work. Initial data from the daily dose-escalation arm, with a possible early look at weekly dosing, are expected in the first half of 2027.

Shareholders will vote on substantial additional issuance authorityA September extraordinary meeting introduces a clear potential dilution catalyst despite the company's currently strong liquidity.

The board called an extraordinary general meeting for September 30 seeking authority to allot and issue up to 90 million additional Class A ordinary shares and waive related pre-emption rights. The authorization does not itself constitute an issuance, but it would give management significant additional financing and strategic flexibility after already completing two large private placements during 2026.

Loading local price history

Revenue

2021

2022

2023

2024

2025

Net income

2021

2022

2023

2024

2025

Free cash flow

2021

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021
Revenue	$5.0M	$0	$5.0M	$0	$45.7M
Research & development	$32.8M	$44.9M	$58.2M	$54.5M	$42.1M
Operating expenses	$40.7M	$52.9M	$72.6M	$67.3M	—
Operating income	−$35.7M	−$52.9M	−$72.6M	−$67.3M	−$8.6M
Operating margin	−713.96%	—	−1,451.02%	—	−18.91%
EBITDA	−$32.6M	−$52.4M	−$72.1M	−$66.7M	—
EBITDA margin	−652.54%	—	−1,441.72%	—	—
Net income	−$35.5M	−$51.9M	−$109.2M	−$58.8M	−$56.7M
Net profit margin	−710.56%	—	−2,184.56%	—	−123.95%
Basic EPSper basic share	-$1.11	-$0.54	-$2.52	-$2.31	-$2.23
Diluted EPSper diluted share	-$1.11	-$0.54	-$2.52	-$2.31	-$2.23

Review official source filings ↗

Owners

Reported shareholders

Ownership data is not available for this listing yet.

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)1$131.80 disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
May 13, 2026Form 4	LU YANGCEO	SellAmerican Depositary Shares	10	$13.18	$131.80	100.0K

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about ANL yet. Start the conversation.

Write the first post

Adlai Nortye Group Ltd. (ANL)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.